Klaudia Farkas

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

K Gecse, Barbara D. Lovász, Klaudia Farkas et al. · Journal of Crohn s and Colitis · 2015 · 182 citations · Full text

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

László Kiss, Tamás Szamosi, Tamás Molnár et al. · Alimentary Pharmacology & Therapeutics · 2011 · 159 citations · Full text

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center

Klaudia Farkas, Mariann Rutka, Anita Bálint et al. · Expert Opinion on Biological Therapy · 2015 · 92 citations

Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy

Tamás Molnár, Péter L. Lakatos, Klaudia Farkas et al. · Alimentary Pharmacology & Therapeutics · 2012 · 85 citations · Full text

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis

Klaudia Farkas, Mariann Rutka, Petra A. Golovics et al. · Journal of Crohn s and Colitis · 2016 · 81 citations · Full text